{"product_id":"acorda-business-model-canvas","title":"Acorda Therapeutics Business Model Canvas","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eFeatures a comprehensive, pre-written business model tailored to Acorda Therapeutics' strategy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses company strategy into a digestible format for quick review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eWhat you see here is the complete Acorda Therapeutics Business Model Canvas. This preview is an exact representation of the final document. Purchasing grants you immediate access to the same file, ready for your analysis. It includes all sections and details. No changes, just the full, ready-to-use Canvas. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBusiness Model Canvas Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcorda's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Acorda Therapeutics's strategy with our Business Model Canvas. This tool maps key partners, activities, and value propositions. Understand their customer segments and revenue streams. Analyze cost structures and uncover growth opportunities. Get the full canvas now for in-depth insights!\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerz Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn July 2024, Merz Therapeutics acquired key assets from Acorda Therapeutics, including INBRIJA and (F)AMPYRA. This partnership is crucial for patients, ensuring continued access to these medications. Merz's acquisition strengthens its neurology portfolio, with a focus on Parkinson's and multiple sclerosis. The deal demonstrates Merz's commitment to expanding its therapeutic offerings. The acquisition significantly boosts Merz's revenue, with INBRIJA sales alone reaching $50 million in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics previously partnered with Biogen for FAMPYRA's commercialization outside the U.S. This key partnership concluded in January 2024, with Acorda taking over global rights. The collaboration aimed to increase FAMPYRA's availability to multiple sclerosis patients. Acorda and Biogen are working to ensure a seamless patient transition. In 2024, FAMPYRA generated $140 million in net revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatalent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn January 2021, Acorda Therapeutics and Catalent finalized an agreement. Catalent acquired Acorda's INBRIJA manufacturing operations. This strategic move included a long-term global supply agreement. Catalent now manufactures and packages INBRIJA for Acorda. This ensures a continuous drug supply for patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChance Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics partnered with Chance Pharmaceuticals to distribute INBRIJA in China, aiming to increase its market reach. This collaboration was crucial for expanding INBRIJA's availability to Chinese patients. The deal aligns with Acorda's strategy to explore global markets. This partnership is a key component of Acorda's business model. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution and Supply Agreement:\u003c\/strong\u003e Acorda and Chance Pharmaceuticals' agreement to distribute INBRIJA in China.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e The partnership's goal of making INBRIJA available to patients in the Chinese market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Alignment:\u003c\/strong\u003e The partnership fits Acorda's broader strategy of global market exploration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBusiness Model Component:\u003c\/strong\u003e Highlights the partnership's role in Acorda's business model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopas Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics strategically partnered with Biopas Laboratories to expand INBRIJA's reach into Latin America. This key partnership facilitated the distribution and supply of INBRIJA, aiming to improve accessibility for patients in the region. By collaborating with Biopas, Acorda was able to leverage local market expertise and infrastructure. This move highlights Acorda's focus on global expansion and patient access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAgreement:\u003c\/strong\u003e Distribution and supply agreement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e INBRIJA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegion:\u003c\/strong\u003e Latin America.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGoal:\u003c\/strong\u003e Expand patient access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcorda's Global INBRIJA Expansion: Partnerships Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda partnered with Chance Pharmaceuticals for INBRIJA distribution in China, boosting market reach. This strategic alignment enabled Acorda to tap into the Chinese market. The collaboration underscores Acorda's commitment to global expansion.\u003c\/p\u003e\n\u003cp\u003eAcorda's partnership with Biopas Laboratories expanded INBRIJA's reach in Latin America via distribution and supply. The goal was to improve accessibility. Biopas' local expertise was a key advantage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChance Pharma\u003c\/td\u003e\n\u003ctd\u003eINBRIJA\u003c\/td\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopas Labs\u003c\/td\u003e\n\u003ctd\u003eINBRIJA\u003c\/td\u003e\n\u003ctd\u003eLatin America\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerz Therapeutics\u003c\/td\u003e\n\u003ctd\u003eINBRIJA, FAMPYRA\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapy Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics concentrated on creating treatments to aid individuals with neurological conditions. This involved extensive research and development efforts. Their key activities included discovering and advancing therapies for diseases like multiple sclerosis and Parkinson's disease. In 2024, the company continued to invest in its pipeline. It aimed to enhance existing treatments and explore new therapeutic avenues. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercialization was a central activity for Acorda Therapeutics, focusing on its approved drugs. Key efforts included marketing, sales, and distribution. These activities ensured AMPYRA and INBRIJA reached patients. In 2023, Acorda's net product revenue was $60.2 million. This reflects the importance of effective commercial strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics previously managed the manufacturing of its products. However, in 2019, Acorda sold its manufacturing operations to Catalent. Maintaining a reliable, high-quality supply chain for its medications was crucial. This was especially important for products like Ampyra, a key revenue driver. By 2024, Ampyra's sales were significantly impacted due to generic competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating the complex regulatory landscape was crucial for Acorda Therapeutics, making it a key activity. This involved securing and keeping regulatory approvals for its products. Acorda had to strictly follow all pertinent regulations and guidelines to ensure compliance. In 2024, the pharmaceutical industry faced increased scrutiny, with the FDA implementing stricter guidelines. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eFDA inspections and compliance checks were frequent.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAcorda spent a substantial part of its budget on regulatory affairs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company's success hinged on its ability to meet regulatory standards.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory compliance directly impacted product launch timelines.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics strategically formed partnerships to broaden its market presence and operational capacity. These alliances were crucial for commercializing and distributing its products. The company also engaged in collaborations to secure its supply chain across different regions. These partnerships were fundamental to Acorda's growth strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, Acorda's partnerships likely contributed to its market expansion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCollaborations aided in product distribution and supply chain management.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese alliances were vital for Acorda's commercial success.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships helped navigate various regulatory landscapes.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcorda's 2023 Revenue: $60.2M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics focused on R\u0026amp;D for neurological treatments. Commercialization efforts included marketing and sales for approved drugs like AMPYRA and INBRIJA. Regulatory compliance and strategic partnerships were critical for market access. Acorda's net product revenue was $60.2 million in 2023. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eResearch \u0026amp; development of neurological treatments\u003c\/td\u003e\n\u003ctd\u003eDrug discovery \u0026amp; pipeline development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing, sales, and distribution of approved drugs\u003c\/td\u003e\n\u003ctd\u003eRevenue generation, market reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring \u0026amp; maintaining regulatory approvals\u003c\/td\u003e\n\u003ctd\u003eCompliance, product launch timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eStrategic alliances for market presence and operational capacity\u003c\/td\u003e\n\u003ctd\u003eMarket expansion, distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics heavily relied on its intellectual property. This included patents protecting drugs like Ampyra and other proprietary knowledge. These assets were key for market exclusivity.\u003c\/p\u003e\n\u003cp\u003eIn 2024, maintaining and defending these patents was critical. This protected its innovations and market position. This strategy helped Acorda's products generate revenue.\u003c\/p\u003e\n\u003cp\u003eAcorda's IP portfolio was vital for attracting investors. It also helped the company with strategic partnerships. Protecting these assets was essential.\u003c\/p\u003e\n\u003cp\u003eThe company's success depended on its ability to leverage this intellectual property. This includes seeking new patents for future products.\u003c\/p\u003e\n\u003cp\u003eAcorda's IP strategy aimed to maximize product lifecycles. This ensured sustained financial returns and competitive advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMPYRA\/FAMPYRA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMPYRA (dalfampridine) in the U.S. and FAMPYRA (fampridine) outside the U.S. were crucial revenue drivers for Acorda Therapeutics. These drugs improved walking ability in multiple sclerosis patients. In 2024, their sales figures are essential for assessing Acorda's market position. Focusing on these assets helps evaluate the company's overall financial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINBRIJA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINBRIJA (levodopa inhalation powder) was a crucial resource for Acorda Therapeutics. It provided an innovative way to manage OFF episodes in Parkinson's patients. In 2023, INBRIJA generated approximately $41.2 million in net revenue. This underscores its significance in their business model. The product’s inhalation delivery offered a distinct advantage for patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARCUS Pulmonary Delivery System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics' ARCUS pulmonary delivery system was a critical technological asset. It was designed to deliver medications via inhalation. This innovative approach aimed to improve drug administration. Acorda invested significantly in this platform. The platform's development costs were a factor in the company's financial performance, especially in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAcorda's R\u0026amp;D expenses in 2024 were substantial, impacting profitability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eARCUS aimed to enhance the delivery of therapies like inhaled levodopa.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe system's success hinged on regulatory approvals and market adoption.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIts potential for faster drug absorption was a key advantage.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics' brand reputation was crucial, positioning it as a leader in neurological disorder treatments. This positive image fostered trust with patients, doctors, and collaborators. A strong reputation could influence product adoption and partnerships. In 2024, maintaining this reputation was vital for Acorda's success as it navigated market challenges. This reputation directly impacted its ability to attract investment and support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Trust:\u003c\/strong\u003e A good reputation builds confidence in treatment efficacy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealthcare Professional Trust:\u003c\/strong\u003e Reputation influences prescribing decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePartnerships:\u003c\/strong\u003e Positive image attracts collaborations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestment:\u003c\/strong\u003e Strong brand aids in attracting financial support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtecting Assets: A 2024 Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda’s intellectual property, crucial for market exclusivity, included patents protecting key drugs. In 2024, protecting these assets was essential for maintaining its market position and revenue generation. This strategy was vital for attracting investors and strategic partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Resources\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Data Snapshot\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property\u003c\/td\u003e\n\u003ctd\u003ePatents \u0026amp; proprietary knowledge.\u003c\/td\u003e\n\u003ctd\u003ePatent maintenance costs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMPYRA\/FAMPYRA\u003c\/td\u003e\n\u003ctd\u003eRevenue-generating drugs.\u003c\/td\u003e\n\u003ctd\u003eSales figures for 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINBRIJA\u003c\/td\u003e\n\u003ctd\u003eLevodopa inhalation.\u003c\/td\u003e\n\u003ctd\u003e$41.2M net revenue (2023).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Walking Ability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics' AMPYRA (FAMPYRA outside the US) was designed to improve walking in multiple sclerosis patients. Clinical trials showed a positive impact on walking speed, confirmed by data. In 2024, the drug continued to be a key offering, despite financial challenges. This improvement directly boosted patient mobility and quality of life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntermittent Treatment of OFF Episodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINBRIJA addressed the challenge of OFF episodes in Parkinson's patients, offering a timely solution. This on-demand treatment improved motor control, and daily functioning. In 2024, the market for Parkinson's drugs continues to grow, with INBRIJA playing a part. It shows Acorda's commitment to patient-focused solutions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Delivery System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda Therapeutics' ARCUS pulmonary delivery system was a groundbreaking innovation. It provided a fast and precise way to administer drugs via inhalation, enhancing their effectiveness. This technology was designed to improve patient outcomes by ensuring that medication reached the lungs swiftly and efficiently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Neurological Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics' value proposition centered on neurological disorders. This specialization enabled the development of targeted therapies. Focused products met the specific needs of affected patients. In 2024, the neurological therapeutics market was valued at approximately $35 billion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSpecialized focus on neurological conditions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDevelopment of targeted therapies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProducts designed for specific patient needs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket size in 2024 was around $35 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUninterrupted Medication Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAcorda Therapeutics focused on guaranteeing a steady medication supply through partnerships and supply agreements. This commitment was vital for patients relying on their treatments, particularly those managing chronic conditions. By ensuring continuous access, Acorda aimed to reduce disruptions in patient care and improve outcomes. This proactive approach underscored their dedication to patient well-being. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, Acorda's key medications, such as Inbrija, needed reliable supply chains.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic alliances were essential to maintain a consistent flow of these drugs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatient adherence to treatment plans was a top priority, influenced by supply stability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company focused on minimizing supply chain risks for critical therapies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhancing Mobility and Motor Control with Targeted Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcorda’s value propositions included therapies like AMPYRA and INBRIJA, enhancing patient mobility and motor control, respectively. They provided solutions for neurological conditions, addressing specific patient needs. A focus on consistent medication supply improved treatment adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eValue Proposition\u003c\/th\u003e\n\u003cth\u003eBenefit\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMPYRA\u003c\/td\u003e\n\u003ctd\u003eImproved walking in MS patients\u003c\/td\u003e\n\u003ctd\u003eEnhanced mobility \u0026amp; quality of life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINBRIJA\u003c\/td\u003e\n\u003ctd\u003eReduced OFF episodes in Parkinson's\u003c\/td\u003e\n\u003ctd\u003eImproved motor control \u0026amp; daily functioning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedication Supply\u003c\/td\u003e\n\u003ctd\u003eReliable access to treatments\u003c\/td\u003e\n\u003ctd\u003eReduced disruptions in care, better outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":55892515389824,"sku":"acorda-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/acorda-business-model-canvas.png?v=1745138706","url":"https:\/\/swotanalysistemplates.com\/products\/acorda-business-model-canvas","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}